TL;DR

A market moving toward engineered materials, not biological dependence 

Recent reimbursement and market dynamics in the US are changing how wound repair materials are selected. The 2026 CMS Physician Fee Schedule introduces a flat-rate reimbursement model (~$127/cm²), replacing the previous ASP-based system. This is placing direct pressure on biologic materials that depend on complex sourcing, preservation, and high-cost supply chains. 

The response from the market has been decisive. Solventum’s acquisition of Acera Surgical (Restrata) reflects a clear move toward synthetic electrospun matrices with predictable cost structures and scalable manufacturing. At the same time, companies such as Smith+Nephew and ConvaTec are expanding their focus on engineered wound-facing materials where performance can be defined and reproduced consistently, as exemplified with their Allevyn and Hydrofiber technology platforms. 

Across wound repair, the focus is shifting from materials that demonstrate promise in controlled settings to materials that can be engineered, manufactured, and relied on at scale. 

Where performance really matters in wound and tissue-facing applications 

Wound repair spans a wide range of applications, from surface-level dressings to internal soft tissue reinforcement. At the more demanding end of this spectrum, such as dural repair, expectations on material performance are significantly higher. Mechanical strength and structural integrity are not optional features; it is defined requirements that must be delivered consistently. 

Teams are no longer selecting materials based on individual properties alone, but on how they behave as a system across handling, placement, manufacturing and clinical use. For example, coating an electrospun scaffold with hyaluronic acid may not only support tissue response, but also help reduce adhesions to surrounding organs in abdominal wound repair. Material decisions made early in development can directly influence later-stage programme outcomes, including manufacturing consistency, validation strategy, regulatory confidence, and ultimately commercial viability.  

In practice, this means being able to define and reproduce: 

• fluid management within the application environment  

• conformability and contact with tissue  

• structural integrity during handling and deployment  

• consistency in behaviour across batches and production runs  

The goal is to design materials where the biological and mechanical behaviour is controlled from the outset. 

Where biologics create limitations for scale and reproducibility 

Biologic materials have historically played a strong role in wound care, particularly where reimbursement supported high-cost solutions. That environment is changing. Today, the limitations are more visible: 

• cost structures that are difficult to sustain under flat-rate reimbursement  

• variability linked to biological sourcing  

• constraints in scalability and manufacturing consistency  

• logistical complexity in storage and handling  

As a result, the focus is shifting toward synthetic and biosynthetic materials that can deliver similar biological cues while offering greater control, reproducibility, and commercial viability.  

Electrospinning, Now a Viable Commercial and Clinical Technology 

Electrospinning is ideally positioned to facilitate this shift. However, a deep knowledge of the right material design parameters, such as polymer chemistry, fibre diameter and porosity, orientation, and sequence of layering, as well as process knowledge in scale-up, yield, and production consistency is necessary.  

Electrospun structures can replicate key aspects of extracellular matrix environments while maintaining the consistency of a synthetic system. This combination is what allows them to move from concept into real product development. 

The market has already validated this approach. Products such as Restrata demonstrate that electrospun matrices can achieve regulatory clearance, clinical adoption, and commercial traction within highly competitive wound care markets. More importantly, electrospinning is no longer viewed as an emerging laboratory technology, but as a viable route for developing commercially relevant wound-facing products with controlled architecture and reproducible performance. This shift is changing how companies evaluate electrospinning partners and material platforms. The differentiator is no longer access to electrospinning itself, but the ability to translate electrospun structures into controlled, device-grade materials supported by robust process development, scale-up experience, manufacturing consistency, and regulatory alignment. In practice, this means understanding how fibre architecture, material composition, and process parameters influence not only biological performance, but also yield, repeatability, handling, sterilisation compatibility, and long-term manufacturability.. 

Where The Electrospinning Company fits 

At The Electrospinning Company, electrospinning is applied as part of a development and manufacturing framework that helps partners translate material concepts into functional, repeatable, and regulated device components. Through the Symatix® technology platform and the Mimetix platform, The Electrospinning Company supports teams in developing electrospun materials with defined fibre architecture, composition, and performance targets, translating early material concepts into controlled, manufacturable components produced under ISO 13485-aligned systems. 

This approach is grounded in real product and manufacturing experience within regulated soft tissue applications. Our work on electrospun materials for dural repair, including ArtiFascia® dural graft (Nurami), required precise control over cell ingrowth, degradation kinetics, and mechanical reliability in an application where performance expectations are among the highest in soft tissue repair. 

That experience translates directly into other wound and tissue-facing applications. It enables programmes where material behaviour is not assumed, but specified, engineered, and reproduced consistently. In practice, this means: 

• defining performance at the application level, not just the material level  

• engineering fibre structures to deliver targeted behaviour  

• scaling processes without drift in performance  

• process monitoring and control of key sources of variation, and data-driven quality systems 

• manufacturing under ISO 13485 with full traceability  

• supporting development through regulatory and validation stages  

This is where The Electrospinning Company differentiates. Not by offering electrospinning as a service, but by delivering controlled material platforms that support progression from concept to a clinically validated and commercially competitive product. 

Conclusion and next steps 

Wound repair is moving toward materials that are engineered to perform predictably under real conditions. In many cases, the principles required to achieve this are already established in demanding applications such as dural repair. In many of the highest-value wound healing indications, the transition toward next-generation material systems is already underway. In advanced skin repair, the market is moving beyond traditional biologics toward synthetic and biosynthetic matrices that offer better scalability and reproducibility under increasing reimbursement pressure. In abdominal and hernia repair, there is growing demand for lightweight, conformable materials that support tissue integration while reducing stiffness and adhesion-related complications. Internal soft tissue applications, including dural repair, are already demonstrating how controlled electrospun architectures can support demanding requirements around fluid interaction, structural integrity, and regenerative performance. 

The opportunity now is to apply that level of control systematically across wound repair, using material platforms that are designed for consistency, scalability, and regulatory alignment from the outset. 

If you are evaluating material strategies or exploring alternatives, we would be happy to discuss how electrospun platforms can support your development pathway. 

FAQs 

What makes electrospun materials different from traditional wound repair materials? Electrospun materials are defined by their fibre architecture, allowing fluid behaviour, mechanical response, and tissue interaction to be controlled more precisely than conventional materials. 

Are electrospun materials scalable for commercial manufacturing? Yes, when supported by controlled processes and manufacturing systems that maintain consistency in structure and performance under regulated conditions. 

Why is dural repair relevant to wound material development? The structural, mechanical, and chemical requirements for dural and dermal regeneration are highly comparable. Both processes rely on the same primary cells and follow identical tissue regeneration pathways. Consequently, advanced materials in both fields, such as ArtiFascia and Restrata, utilize structurally and chemically similar matrices to mimic the native tissue and support this shared biological response. 

What should teams consider when selecting a material platform? Beyond biological performance, teams should consider how well a material can be defined, controlled, and manufactured consistently at scale. 

How can The Electrospinning Company support development programmes? The Electrospinning Company works with partners through platforms such as the Symatix technology platform and the Mimetix platform to design, scale, and manufacture electrospun materials for regulated applications.